• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Management of dyslipidemia in Poland: Interdisciplinary Expert Position Statement endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy. The Fourth Declaration of Sopot.

作者信息

Szymański Filip M, Mickiewicz Agnieszka, Dzida Grzegorz, Gorczyca-Głowacka Iwona, Kozłowski Dariusz, Widecka Krystyna, Krasiński Zbigniew, Kobayashi Adam, Hering Dagmara, Mizia-Stec Katarzyna, Kasprzak Jarosław D, Zubilewicz Tomasz, Narkiewicz Krzysztof, Koziński Marek, Płatek Anna E, Ryś-Czaporowska Anna, Chełstowska Beata, Grajek Stefan, Wełnicki Marcin, Mamcarz Artur, Barylski Marcin, Wożakowska-Kapłon Beata, Jaguszewski Miłosz J, Gruchała Marcin, Filipiak Krzysztof J

机构信息

Department of Civilization Diseases, Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszynski University in Warsaw, Poland.

1st Department of Cardiology, Medical University of Gdansk, Poland.

出版信息

Cardiol J. 2022;29(1):1-26. doi: 10.5603/CJ.a2021.0147. Epub 2021 Nov 23.

DOI:10.5603/CJ.a2021.0147
PMID:34811718
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8890423/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/804b/8890423/341b068518c6/cardj-29-1-1f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/804b/8890423/e1d1d0995f65/cardj-29-1-1f1a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/804b/8890423/e2c1d7fc9569/cardj-29-1-1f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/804b/8890423/9b352da3dc28/cardj-29-1-1f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/804b/8890423/3bbafbf78d49/cardj-29-1-1f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/804b/8890423/238c64325a63/cardj-29-1-1f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/804b/8890423/142a4b08d918/cardj-29-1-1f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/804b/8890423/8daa0c0a41c1/cardj-29-1-1f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/804b/8890423/341b068518c6/cardj-29-1-1f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/804b/8890423/e1d1d0995f65/cardj-29-1-1f1a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/804b/8890423/e2c1d7fc9569/cardj-29-1-1f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/804b/8890423/9b352da3dc28/cardj-29-1-1f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/804b/8890423/3bbafbf78d49/cardj-29-1-1f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/804b/8890423/238c64325a63/cardj-29-1-1f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/804b/8890423/142a4b08d918/cardj-29-1-1f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/804b/8890423/8daa0c0a41c1/cardj-29-1-1f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/804b/8890423/341b068518c6/cardj-29-1-1f8.jpg

相似文献

1
Management of dyslipidemia in Poland: Interdisciplinary Expert Position Statement endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy. The Fourth Declaration of Sopot.波兰血脂异常管理：由波兰心脏学会心血管药物治疗工作组认可的跨学科专家立场声明。索波特第四次声明。
Cardiol J. 2022;29(1):1-26. doi: 10.5603/CJ.a2021.0147. Epub 2021 Nov 23.
2
Recommendation for the management of dyslipidemia in Poland - Third Declaration of Sopot. Interdisciplinary Expert Position Statement endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy.波兰血脂异常管理建议——索波特第三次声明。由波兰心脏学会心血管药物治疗工作组认可的跨学科专家立场声明。
Cardiol J. 2018;25(6):655-665. doi: 10.5603/CJ.2018.0141.
3
[Actual problems of dyslipidaemia treatment in Poland - 2nd Declaration of Sopot. Experts' Group Consensus endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy].[波兰血脂异常治疗的实际问题——索波特第二次声明。波兰心脏学会心血管药物治疗工作组认可的专家小组共识]
Kardiol Pol. 2014;72(9):847-53. doi: 10.5603/KP.2014.0182.
4
[Fondaparinux in the treatment of acute coronary syndromes in Poland--from theory to practice. Experts' group position paper endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy].[磺达肝癸钠在波兰急性冠状动脉综合征治疗中的应用——从理论到实践。波兰心脏学会心血管药物治疗工作组认可的专家组立场文件]
Kardiol Pol. 2015;73(10):943-8. doi: 10.5603/KP.2015.0181.
5
Single-pill combinations (SPCs) and treatment of arterial hypertension in Poland. Expert consensus statement of the Polish Society of Hypertension and Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy.单片复方制剂（SPCs）与波兰的动脉高血压治疗。波兰高血压学会和波兰心脏学会心血管药物治疗工作组专家共识声明
Kardiol Pol. 2017;75(12):1357-1367. doi: 10.5603/KP.2017.0237.
6
Polish Forum for Prevention Guidelines on Dyslipidaemia: update 2016.波兰血脂异常预防指南论坛：2016年更新版
Kardiol Pol. 2017;75(2):187-190. doi: 10.5603/KP.2017.0031.
7
[Loop diuretics: old and new ones--which one to choose in clinical practice? Experts' Group Consensus endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy and Working Group on Heart Failure].[袢利尿剂：新旧品种——临床实践中该如何选择？波兰心脏学会心血管药物治疗工作组及心力衰竭工作组认可的专家小组共识]
Kardiol Pol. 2015;73(3):225-32. doi: 10.5603/KP.2015.0051.
8
Re: Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease.关于：加拿大心血管学会立场声明——血脂异常的诊断与治疗及心血管疾病预防的建议
Can J Cardiol. 2007 May 1;23(6):481-2; author reply 483. doi: 10.1016/s0828-282x(07)70793-6.
9
[Type 2 diabetes prevention. Experts' Group position paper endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy].[2型糖尿病的预防。波兰心脏学会心血管药物治疗工作组认可的专家小组立场文件]
Kardiol Pol. 2015;73(10):949-57. doi: 10.5603/KP.2015.0183.
10
Spanish Interdisciplinary Committee for Cardiovascular Disease Prevention and the Spanish Society of Cardiology position statement on dyslipidemia management. Differences between the European and American guidelines.西班牙心血管疾病预防跨学科委员会及西班牙心脏病学会关于血脂异常管理的立场声明。欧洲和美国指南之间的差异。
Rev Esp Cardiol (Engl Ed). 2014 Nov;67(11):913-9. doi: 10.1016/j.rec.2014.05.008. Epub 2014 Aug 3.

引用本文的文献

1
EASY OR NOT. European-Asian Six countries Yearly consensus On Recent guidelines: arterial hypertension, atrial fibrillation, chronic coronary syndromes, and peripheral artery diseases. Novel Or conventional Treatment options for these patients. Position Paper 2024.易与否。欧亚六国关于近期指南的年度共识：动脉高血压、心房颤动、慢性冠状动脉综合征和外周动脉疾病。这些患者的新型或传统治疗选择。2024年立场文件
Cardiol J. 2025;32(3):213-227. doi: 10.5603/cj.105140. Epub 2025 May 13.
2
Treatment of dyslipidemia in Poland - common diagnostics, early combined therapy. Expert position statement endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy. 5th Declaration of Sopot.波兰血脂异常的治疗——常见诊断方法、早期联合治疗。波兰心脏学会心血管药物治疗工作组认可的专家立场声明。索波特第五份声明。
Cardiol J. 2025;32(2):107-119. doi: 10.5603/cj.103680. Epub 2025 Mar 31.
3

本文引用的文献

1
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.2021年欧洲心脏病学会临床实践中心血管疾病预防指南。
Eur Heart J. 2021 Sep 7;42(34):3227-3337. doi: 10.1093/eurheartj/ehab484.
2
Lipoprotein (a): When to Measure and How to Treat?脂蛋白(a)：何时检测及如何治疗？
Curr Atheroscler Rep. 2021 Jul 8;23(9):51. doi: 10.1007/s11883-021-00951-2.
3
The Riskier Lipid: What Is on the HORIZON for Lipoprotein (a) and Should There Be Lp(a) Screening for All?风险更高的脂质：脂蛋白（a）的前景如何，是否应对所有人进行脂蛋白（a）筛查？
Lipoprotein(a) and thromboembolism: current state of knowledge and unsolved issues.脂蛋白(a)与血栓栓塞：当前的知识现状及未解决的问题。
Arch Med Sci. 2024 Dec 13;20(6):1770-1783. doi: 10.5114/aoms/197357. eCollection 2024.
4
Reduced Oxidative Susceptibility of Lp(a) and LDL Fractions as a Pleiotropic Effect of Lipoprotein Apheresis in Patients with Elevated Lp(a) and ASCVDs.脂蛋白分离术对Lp(a)升高和患有动脉粥样硬化性心血管疾病（ASCVDs）患者的多效性作用：Lp(a)和低密度脂蛋白（LDL）组分氧化敏感性降低
Int J Mol Sci. 2024 Dec 19;25(24):13597. doi: 10.3390/ijms252413597.
5
Nutritional Management of Dyslipidemia in Pakistan: A Systematic Review of International Guidelines and Practices.巴基斯坦血脂异常的营养管理：国际指南与实践的系统评价
Oman Med J. 2024 May 30;39(3):e645. doi: 10.5001/omj.2024.81. eCollection 2024 May.
6
Lipoprotein (a) and the Occurrence of Lipid Disorders and Other Cardiovascular Risk Factors in Patients without Diagnosed Cardiovascular Disease.脂蛋白（a）与未诊断为心血管疾病患者的脂质紊乱及其他心血管危险因素的发生情况
J Clin Med. 2024 Aug 8;13(16):4649. doi: 10.3390/jcm13164649.
7
Statins use amidst the pandemic: prescribing, dispensing, adherence, persistence, and correlation with COVID-19 statistics in nationwide real-world data from Poland.疫情期间他汀类药物的使用情况：波兰全国真实世界数据中的处方开具、配药、依从性、持续性以及与新冠肺炎统计数据的相关性
Front Pharmacol. 2024 Apr 9;15:1350717. doi: 10.3389/fphar.2024.1350717. eCollection 2024.
8
Lipoprotein apheresis affects the concentration of extracellular vesicles in patients with elevated lipoprotein (a).脂蛋白吸附术影响脂蛋白(a)升高患者细胞外囊泡的浓度。
Sci Rep. 2024 Feb 2;14(1):2762. doi: 10.1038/s41598-024-51782-5.
9
Case report: lipoprotein apheresis reduces the risk of cardiovascular events and prolongs pregnancy in a woman with severely elevated lipoprotein(a), cardiovascular disease, and a high risk of preeclampsia.病例报告：脂蛋白分离术降低了一名脂蛋白(a)严重升高、患有心血管疾病且有先兆子痫高风险的女性发生心血管事件的风险并延长了其孕期。
Front Med (Lausanne). 2023 Sep 20;10:1190446. doi: 10.3389/fmed.2023.1190446. eCollection 2023.
Curr Cardiol Rep. 2021 Jul 1;23(8):97. doi: 10.1007/s11886-021-01528-w.
4
"Health outcomes in COPD smokers using heated tobacco products: a 3‑year follow‑up: comment".使用加热烟草制品的慢性阻塞性肺疾病吸烟者的健康结局：一项3年随访：评论
Intern Emerg Med. 2021 Nov;16(8):2331-2333. doi: 10.1007/s11739-021-02753-5. Epub 2021 May 13.
5
Statin intolerance: new data and further options for treatment.他汀类药物不耐受：新数据和治疗的新选择。
Curr Opin Cardiol. 2021 Jul 1;36(4):487-493. doi: 10.1097/HCO.0000000000000874.
6
Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force.降脂联合治疗高风险和极高风险患者的实用指南：欧洲动脉粥样硬化学会工作组的声明。
Atherosclerosis. 2021 May;325:99-109. doi: 10.1016/j.atherosclerosis.2021.03.039. Epub 2021 Apr 13.
7
The effects of foods on LDL cholesterol levels: A systematic review of the accumulated evidence from systematic reviews and meta-analyses of randomized controlled trials.食物对 LDL 胆固醇水平的影响：系统评价和荟萃分析的累积证据综述。
Nutr Metab Cardiovasc Dis. 2021 May 6;31(5):1325-1338. doi: 10.1016/j.numecd.2020.12.032. Epub 2021 Jan 16.
8
Angiopoietin-like proteins inhibitors: New horizons in the treatment of atherogenic dyslipidemia and familial hypercholesterolemia.血管生成素样蛋白抑制剂：治疗动脉粥样硬化性血脂异常和家族性高胆固醇血症的新领域。
Cardiol J. 2023;30(1):131-142. doi: 10.5603/CJ.a2021.0006. Epub 2021 Jan 20.
9
Cardiovascular events in patients with familial hypercholesterolemia and hyperlipoproteinaemia (a): Indications for lipoprotein apheresis in Poland.家族性高胆固醇血症和高脂蛋白血症患者的心血管事件（一）：波兰脂蛋白吸附治疗的适应证。
J Clin Apher. 2021 Jun;36(3):370-378. doi: 10.1002/jca.21872. Epub 2021 Jan 2.
10
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial.阿利西尤单抗降低脂蛋白(a)可降低心血管事件的总体负担，且独立于低密度脂蛋白胆固醇的降低：ODYSSEY OUTCOMES试验
Eur Heart J. 2020 Nov 21;41(44):4245-4255. doi: 10.1093/eurheartj/ehaa649.